233261-85-3

Basic information

• Product Name: 1-(3-Chloro-benzenesulfonyl)-piperazine
• Synonyms: 1-(3-Chloro-benzenesulfonyl)-piperazine
• CAS NO: 233261-85-3
• Molecular Formula: C10H13ClN2O2S
• Molecular Weight: 260.74042
• Mol File: 233261-85-3.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 413.2±55.0 °C(Predicted)
• Appearance: /
• Density: 1.352±0.06 g/cm3(Predicted)
• PKA: 7.73±0.10(Predicted)
• CAS DataBase Reference: 1-(3-Chloro-benzenesulfonyl)-piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-Chloro-benzenesulfonyl)-piperazine(233261-85-3)
• EPA Substance Registry System: 1-(3-Chloro-benzenesulfonyl)-piperazine(233261-85-3)

Safety Data

• Hazardous Substances Data: 233261-85-3(Hazardous Substances Data)

Usage

General Description

1-(3-Chloro-benzenesulfonyl)-piperazine is a chemical compound with the molecular formula C10H13ClN2O2S. It is a piperazine derivative with a chlorine-substituted benzenesulfonyl group attached to the piperazine ring. 1-(3-Chloro-benzenesulfonyl)-piperazine is commonly used in medicinal chemistry as a building block for the synthesis of various pharmaceuticals and biologically active compounds. It has also been studied for its potential applications in the treatment of various diseases, including cancer and neurological disorders. Additionally, it is known to have significant pharmacological activities, making it a target for drug discovery and development. Overall, 1-(3-Chloro-benzenesulfonyl)-piperazine is a versatile and important compound in the field of medicinal chemistry and pharmaceutical research.

Upstream product

• 2888-06-4 3-chlorophenylsulfonyl chloride 

Relevant articles and documents

Discovery of Novel Chromone Derivatives Containing a Sulfonamide Moiety as Anti-ToCV Agents through the Tomato Chlorosis Virus Coat Protein-Oriented Screening Method

A number of novel chromone derivatives containing sulfonamide moieties were designed and synthesized, and the activity of compounds against tomato chlorosis virus (ToCV) was assessed using the ToCVCP-oriented screening method. Comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) models were established based on the dissociation constant (Kd) values of the target compounds, and compound 35 was designed and synthesized with the aid of CoMFA and CoMSIA models. The study of affinity interaction indicated that compound 35 exhibited excellent affinity with ToCVCP with a Kd value of 0.11 μM, which was better than that of the positive control agents xiangcaoliusuobingmi (0.44 μM) and ningnanmycin (0.79 μM). In addition, the in vivo inhibitory effect of compound 35 on the ToCVCP gene was evaluated by the quantitative real-time polymerase chain reaction. ToCVCP gene expression levels of the compound 35 treatment group were reduced by 67.2%, which was better than that of the positive control agent ningnanmycin (59.5%). Therefore, compound 35 can be used as a potential anti-ToCV drug in the future.